ArticleJournal of cellular and molecular medicine2020
Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Therapeutic targeting of adhesion GPCRs: a status update and future potential.Expert opinion on drug discovery · 2026Review
- Structure of the GNature communications · 2025Article
- The nitrone compound OKN-007 delays motor neuron loss and disease progression in the G93A mouse model of amyotrophic lateral sclerosis.Frontiers in neuroscience · 2024Article
- ELTD1 is present in extracellular vesicles derived from endothelial cells as a cleaved extracellular domain which induces in vivo angiogenesis.Journal of extracellular biology · 2022Article
- Article
- ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.Neuro-oncology · 2022Article
- New life for an old therapy: ELTD1 as a downstream target of angiogenesis.Neuro-oncology · 2022Article
- A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.Journal of cellular and molecular medicine · 2022Article
- ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression.Molecular cancer research : MCR · 2021Article
- ELTD1-An Emerging Silent Actor in Cancer Drama Play.International journal of molecular sciences · 2021Review
- ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.Multiple sclerosis and related disorders · 2021Article
- ELTD1 Promotes Gastric Cancer Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through MAPK/ERK Signaling by Regulating CSK.International journal of general medicine · 2021Article
- ELTD1 promotes invasion and metastasis by activating MMP2 in colorectal cancer.International journal of biological sciences · 2021Article
- Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.Journal of cellular and molecular medicine · 2020Article
- Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments.Frontiers in oncology · 2020Review
- Novel approaches to combat chemoresistance against glioblastomas.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- ELTD1 Review: New Regulator of Angiogenesis in Glioma.Current health sciences journalReview
- ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.Neuro-oncology advancesArticle
- Adhesion G protein-coupled receptors in glioblastoma.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 3 countries.
Funding
Abstract
Glioblastoma is an aggressive brain tumour found in adults, and the therapeutic approaches available have not significantly increased patient survival. Recently, we discovered that ELTD1, an angiogenic biomarker, is highly expressed in human gliomas. Polyclonal anti-ELTD1 treatments were effective in glioma pre-clinical models, however, pAb binding is potentially promiscuous. Therefore, the aim of this study was to determine the effects of an optimized monoclonal anti-ELTD1 treatment in G55 xenograft glioma models. MRI was used to assess the effects of the treatments on animal survival, tumour volumes, perfusion rates and binding specificity. Immunohistochemistry and histology were conducted to confirm and characterize microvessel density and Notch1 levels, and to locate the molecular probes. RNA-sequencing was used to analyse the effects of the mAb treatment. Our monoclonal anti-ELTD1 treatment significantly increased animal survival, reduced tumour volumes, normalized the vasculature and showed higher binding specificity within the tumour compared with both control- and polyclonal-treated mice. Notch1 positivity staining and RNA-seq results suggested that ELTD1 has the ability to interact with and interrupt Notch1 signalling. Although little is known about ELTD1, particularly about its ligand and pathways, our data suggest that our monoclonal anti-ELTD1 antibody is a promising anti-angiogenic therapeutic in glioblastomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.